SEC Form 4 · accession 0001179110-18-000394
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Bartram
Officer — Chief Financial Officer
Period of report
Jan 2, 2018
Accepted (ET)
Jan 3, 2018 · 6:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 2, 2018 | M | 17,892 | $3.70 | A | 19,092 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $66.50 | Jan 2, 2018 | A | 38,500 | A | — | Jan 2, 2028 | Common Stock | 38,500 | 38,500 | D |
| Stock Option (right to buy)F2 | $3.70 | Jan 2, 2018 | M | 17,892 | A | — | Apr 24, 2018 | Common Stock | 17,892 | 0 | D |
Explanation of responses
- F1The options vest over a four (4) year period in equal quarterly installments, the first of which will be on April 2, 2018.
- F2The options are fully vested as of the date hereof.